Population pharmacokinetics of abacavir in infants, toddlers and children.

about

Population pharmacokinetics of ciclosporin in Chinese children with aplastic anemia: effects of weight, renal function and stanozolol administration.The role of formulation on the pharmacokinetics of antiretroviral drugs.

P2860

Q37728538-B27C4F5A-D54E-4815-A9D5-F4E3480EEB37 Q38216047-A082D0CA-F9F6-4FCD-9398-D9C780583C43

P2860

Population pharmacokinetics of abacavir in infants, toddlers and children.

Item

http://www.wikidata.org/entity/Q36948138

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Population pharmacokinetics of abacavir in infants, toddlers and children.

@en

type

Item

label

Population pharmacokinetics of abacavir in infants, toddlers and children.

@en

prefLabel

Population pharmacokinetics of abacavir in infants, toddlers and children.

@en

P1476

Population pharmacokinetics of abacavir in infants, toddlers and children.

@en

P2093

Chiara Piana

http://www.w3.org/2001/XMLSchema#string

David Burger

http://www.w3.org/2001/XMLSchema#string

Evelyne Jacqz-Aigrain

http://www.w3.org/2001/XMLSchema#string

Meindert Danhof

http://www.w3.org/2001/XMLSchema#string

Oscar Della Pasqua

http://www.w3.org/2001/XMLSchema#string

Wei Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89

Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study

Abacavir and metabolite pharmacokinetics in HIV-1-infected children and adolescents.

Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.

Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects.

What is the right dose for children?

A review of the pharmacokinetics of abacavir.

Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations?

Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.

Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.

P304

1525-1535

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BCP.12024

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23126277

http://www.w3.org/2001/XMLSchema#string

P932

3690111

http://www.w3.org/2001/XMLSchema#string

Population pharmacokinetics of abacavir in infants, toddlers and children.

about

P2860

P2860

Population pharmacokinetics of abacavir in infants, toddlers and children.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932